Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allo-hMSCs in Treatment Resistant Depression
NCT02675556Phase 1Terminated
- Start
- Oct 2017
- Primary completion
- Mar 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of allogeneic bone marrow-derived human mesenchymal stem cells in major depressive disorder (MDD) (3 arms). Primary endpoint: Treatment-Emergent Serious Adverse Events at 4 weeks. Started Oct 2017; status: terminated.
02
Drugs
allogeneic bone marrow-derived human mesenchymal stem cells
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02675556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02675556.